BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
about
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4Mesothelioma treatment: Are we on target? A reviewModulation of apoptosis sensitivity through the interplay with autophagic and proteasomal degradation pathwaysGenistein suppresses the mitochondrial apoptotic pathway in hippocampal neurons in rats with Alzheimer's diseaseBAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesotheliomaBortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumorsInvestigational approaches for mesothelioma.Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.Proteasome inhibitors in the treatment of multiple myelomaTargeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.Oppositional regulation of Noxa by JNK1 and JNK2 during apoptosis induced by proteasomal inhibitorsBortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.BH3-only proteins in apoptosis at a glanceTargeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization.CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer.Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy.Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent mannerThe cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition.Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231.A new target for proteasome inhibitors: FoxM1Stronger proteasomal inhibition and higher CHOP induction are responsible for more effective induction of paraptosis by dimethoxycurcumin than curcumin.ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.BH3-only proteins and their effects on cancer.Differential proteomics in the search for biomarkers of radiotherapy resistance.Proteasome inhibitors: an expanding army attacking a unique target.Malignant pleural mesothelioma: from the bench to the bedside.Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-κB and the proteasome.Efficacy of bortezomib as first-line treatment for patients with multiple myeloma.Apoptosis inducers in chronic lymphocytic leukemia.Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.Involvement of Noxa in mediating cellular ER stress responses to lytic virus infection.Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance
P2860
Q24294703-744671EB-0C5B-4CF5-AF48-907D6AE2821BQ26800042-04D59038-E24B-4D60-887F-A93141B14233Q27016574-7B830D4E-E00E-45A6-855E-9C1CDB4EA281Q28387305-789CC58B-C223-4D8D-A4C5-4F9B1E2185B8Q28533736-FBD132BA-D7F0-4785-B3C9-4DD004E5E66FQ33747277-374D8F32-DAB5-4161-8533-C7CEA799AD1EQ33862527-B811BD71-7701-4B03-A20C-A044F53BEEF5Q34073160-0A5A5B6A-7D0E-4941-8AA2-5891B52576BAQ34293068-33F14F91-03AF-48C3-8EC2-D1C69E6D4C64Q34541718-E4069FA6-8A16-459D-8533-31D5D6719340Q34602252-7F7368D6-D519-4327-8BB3-E080BC430E24Q34611676-2C314785-E070-4EA8-89EF-6B3B14CFEB8FQ34614482-0DF0EE7A-748A-4CC1-942C-32643C2A4C6DQ34674973-DC6644E6-685C-44AD-8751-3F214D50E38FQ34802998-A11947CA-2C12-4F2F-8071-1829F758F0D5Q35776414-64A96735-270D-4ED9-B8B5-1F66E9013D5AQ35883875-B76D0FB6-24A7-4A53-9D7C-EC1E0F108852Q36037180-C9A2D02C-6439-4198-8C05-2A4B8FE63012Q36170136-8B4A0570-DABC-4BF6-8C49-5910885002D9Q36291183-4A3CE697-9B80-4C3F-85F8-645563E91425Q36526514-E8F49F04-58F1-4FF6-8729-E3EC1220D94DQ36540685-4F1C867D-A256-463E-B0AE-5A981D349EAEQ37146291-524572B7-2F67-4979-89A1-88522D8AB6B4Q37289335-7AB52C54-CB03-4E8F-BDD7-D8201D02AB52Q37360220-D1F5D638-FC01-49D0-8DCF-D4910D177E25Q37631680-471850CD-4104-466C-847E-F081F876DD9FQ37674617-F2DBB2F0-5D94-4C87-A667-23E5033EF4DBQ37680263-A7F8DCB8-9529-40F1-8D7E-F78A14CA88CCQ37712188-7E89F7F6-DE5D-4EB6-A2A7-F75DFE885B4AQ37797387-37EA52F0-2C7C-4327-9E57-2B1E3A10B381Q37912208-0A55D9EC-18C9-40AF-8D40-977FF23E5C68Q37979388-60C44D79-D909-4B56-BFF5-49593EDDB813Q38019747-22DD8671-F265-4EEF-9C20-FE63475E6C8DQ38088360-E0540EC0-63AA-46B9-AA7E-4B5B7637612AQ38089497-75D2BB21-38B2-4F48-8FCE-DA6A031478EAQ38187815-C303CEB5-FEE3-436C-AF29-004A2F63C94CQ38258197-2F3D9E42-83D2-4E73-B66C-FE36167873F2Q38271048-07D9E874-D868-4BFB-8844-A33E57E25C33Q38343228-B9CA4EE8-09DC-4311-9F6D-650E05C1F122Q38347433-99E84F94-4EB6-4B75-BF14-9C723362EE4F
P2860
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
@en
type
label
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
@en
prefLabel
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
@en
P2093
P2860
P356
P1433
P1476
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210744
P407
P577
2007-09-10T00:00:00Z
P5875
P6179
1003677542